English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
STR1VE-EU Trial Shows Efficacy of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Onasemnogene abeparvovec gene replacement therapy effectively helped infants with symptomatic spinal muscular atrophy type 1 (SMA1) achieve at least one episode of independent sitting in a phase 3 clinical trial published in The Lancet Neurology.
Infants with SMA1, the most severe postnatal phenotype, experience motor neuron dysfunction due to the biallelic loss of the survival motor neuron 1 (SMN1) gene. Typically, disease onset is seen at age 6 months and can then progress to a quick decline in motor function. This can lead to death or sometimes permanent ventilation by age 2 years.
Onasemnogene abeparvovec gene replacement therapy, approved by the US Food and Drug Administration (FDA), is able to deliver human SMN via a single intravenous infusion and has shown safety and efficacy in trials that evaluated infants younger than 8 months and younger than 6 months with SMA1, respectively.
BookmarkRelated Content
-
Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy—Protocol ...Spinal muscular atrophy (SMA) is a rare ...
-
Implications of Circulating Neurofilaments for Spinal Muscular Atrophy Treatment Early In Life: A Case SeriesThis longitudinal cohort study aimed to ...
-
SMA Type 1 – Looking After Your Child Who Has Had a Recent DiagnosisThe aim of everyone involved in your chi...
-
Spinal Muscular Atrophy and TypesWhat is Spinal Muscular Atrophy?Spinal m...
-
Spinal Muscular Atrophy: OverviewWhat is spinal muscular atrophy (SMA)?Sp...
-
New Components for Antisense Gene Therapy Show Promise in Treating Spinal Muscular AtrophySkoltech researchers and their colleague...
-
Baby First at UNC to Receive Gene Therapy for SMA, Thanks to Early Check Newborn ScreeningIt was a pregnancy that went relatively ...
Powered by
In partnership with
